Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Contrast Media Mol Imaging. 2022 Jul 22;2022:6094409. doi: 10.1155/2022/6094409. eCollection 2022.
The aim of this study is to explore the diagnostic value of prostate-specific antigen (PSA) combined with serum miRNA-149 expression in prostate cancer (PCa) by conducting experiments and bioinformatics analysis. . 50 PCa patients were enrolled on the experimental group from January 2020 to December 2021. 56 patients with benign prostatic hyperplasia (BPH) were selected as the control group at the same time. Real-time fluorescent quantitative PCR was applied to investigate the miRNA-149 expression. PSA was detected by using a chemiluminescence meter using Abbott i4000. Applying bioinformatics analysis, we explored the expression of hsa-miR-149 in PCa in The Cancer Genome Atlas (TCGA) database. Kaplan-Meier analyses were used to evaluate the prognostic value, and the ROC curve was applied.
The expression level of miRNA-149 in the PCa group was significantly higher than that in the BPH group ( < 0.05). The PSA level in the PCa group was also significantly higher than that in the BPH group ( < 0.05). TCGA data analysis revealed that PCa tissues had significantly increased hsa-miR-149 expression. The results of survival analysis showed that patients with high expression of hsa-miR-149 had better prognosis. Additionally, the pathological N stage of PCa correlates with the hsa-miR-149 expression level ( = 0.002). According to ROC curve analysis, the region under the curve was 0.653, 95% CI: 0.576-0.730.
High expression of serum miRNA-149 is associated with PCa patients. Although combined PSA did not improve the diagnostic efficacy, miRNA-149 has high specificity in the diagnosis of PCa. miRNA-149 might be a novel marker for early diagnosis and prognosis assessment for PCa.
本研究旨在通过实验和生物信息学分析探讨前列腺特异性抗原（PSA）联合血清微小 RNA-149 表达在前列腺癌（PCa）中的诊断价值。
选取 2020 年 1 月至 2021 年 12 月期间的 50 例 PCa 患者作为实验组，同时选取同期 56 例良性前列腺增生（BPH）患者作为对照组。采用实时荧光定量 PCR 检测 miRNA-149 的表达，应用化学发光仪检测 PSA。应用生物信息学分析方法，探讨 TCGA 数据库中 PCa 中 hsa-miR-149 的表达。采用 Kaplan-Meier 分析评估预后价值，并应用 ROC 曲线进行分析。
PCa 组 miRNA-149 表达水平明显高于 BPH 组（ < 0.05），PSA 水平也明显高于 BPH 组（ < 0.05）。TCGA 数据分析显示，PCa 组织中 hsa-miR-149 的表达显著增加。生存分析结果表明，hsa-miR-149 高表达患者预后较好。此外，PCa 的病理 N 分期与 hsa-miR-149 的表达水平相关（ = 0.002）。根据 ROC 曲线分析，曲线下面积为 0.653，95%CI：0.576-0.730。
血清 miRNA-149 高表达与 PCa 患者相关。虽然联合 PSA 并未提高诊断效能，但 miRNA-149 在 PCa 的诊断中具有较高的特异性。miRNA-149 可能成为 PCa 早期诊断和预后评估的新标志物。
